Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials.
Hillary Stires(Friends of Cancer Research), Jeff Allen(Friends of Cancer Research), Adam Rosenthal(Cancer Research And Biostatistics), Carin R. Espenschied(Guardant (United States)), Névine Zariffa(Alliance for Decision Education), Antje Hoering(Cancer Research And Biostatistics), Anna M. Szpurka(Eli Lilly (United States)), Minakshi Guha(Vedantra Pharmaceuticals (United States)), Mark Stewart(Friends of Cancer Research), Dilafruz Juraeva(Merck KGaA, Darmstadt (Germany)), Gary A. Pestano(SpectraDynamics (United States)), Emily Goren(Cancer Research And Biostatistics), Sorena Rahmanian(University of California San Diego), Katherine K. Nishimura(Cancer Research And Biostatistics), Brittany A. McKelvey(Friends of Cancer Research), Jiannan Guo(University of Washington), Megan Eisele(Cancer Research And Biostatistics), Diana Merino Vega(AstraZeneca (Japan)), Jean‐François Martini(Hôpital Necker-Enfants Malades)
Cited by 4
Related Papers
Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0
|Nature Protocols|2011|1.9k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721